Document Detail


Failure of intravenous pindolol to reduce the hemodynamic determinants of myocardial oxygen demand or enzymatically determined infarct size in acute myocardial infarction.
MedLine Citation:
PMID:  3914879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pindolol, a beta blocker with intrinsic sympathomimetic activity, was investigated in a randomised controlled trial of 100 patients presenting within 12 hours of uncomplicated acute myocardial infarction. Pindolol was given intravenously for 24 hours and orally for 48 hours to achieve serum levels above 10 ng/ml. Heart rate and arterial pressure, both systolic and diastolic, fell to a similar degree in actively treated and control patients. There was no significant difference between systolic blood pressure-heart rate product in actively treated and control patients during the first 72 hours of therapy. There was no increased incidence of cardiac failure, bradycardia, or AV conduction disturbance among pindolol-treated patients. Infarct size estimated from cumulative enzyme release did not differ significantly from controls regardless of whether pindolol was given within four hours or between four and 12 hours of symptom onset. However, fewer patients given pindolol within four hours required morphine. Use of pindolol during the acute phase of myocardial infarction did not appear to modify clinical course, hemodynamic determinants of myocardial oxygen demand, or enzymatically determined infarct size.
Authors:
D A Owensby; M F O'Rourke
Related Documents :
3711489 - Elevated serum d dimer: a degradation product of cross-linked fibrin (xdp) after intrav...
7549079 - Thrombolysis in the era of the randomized trials.
17692949 - Antioxidant status of south indian patients undergoing coronary artery bypass graft sur...
3275209 - Multifocal atrial tachycardia responsive to parenteral magnesium.
3624659 - Paradoxic elevation of fibrinopeptide a after streptokinase: evidence for continued thr...
2140889 - Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic th...
14713119 - Hypoxic induction of myocardial vascularization during development.
24411409 - Advances in sudden death prevention: the emerging role of a fully subcutaneous defibril...
8665369 - Circadian rhythms and the onset of myocardial infarction: clinical implications.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Australian and New Zealand journal of medicine     Volume:  15     ISSN:  0004-8291     ISO Abbreviation:  Aust N Z J Med     Publication Date:  1985 Dec 
Date Detail:
Created Date:  1986-05-30     Completed Date:  1986-05-30     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1264322     Medline TA:  Aust N Z J Med     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  704-11     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Blood Pressure / drug effects
Clinical Trials as Topic
Creatine Kinase / blood
Female
Heart Rate / drug effects
Hemodynamics / drug effects*
Humans
Injections, Intravenous
Male
Middle Aged
Morphine / therapeutic use
Myocardial Infarction / drug therapy,  enzymology,  metabolism*
Oxygen Consumption / drug effects*
Pindolol / administration & dosage*,  blood
Random Allocation
Time Factors
Chemical
Reg. No./Substance:
13523-86-9/Pindolol; 57-27-2/Morphine; EC 2.7.3.2/Creatine Kinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patient selection for cardiac transplantation.
Next Document:  Juxtaglomerular tumour: diagnostic renal vein renin measurements obscured by chronic captopril thera...